Anticoagulant Therapy in Sepsis. The Importance of Timing.

J Crit Care Med (Targu Mures) · 2017 · PMC5769917 · PMID 29967873

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The KyberSept trial failed to reveal efficacy concerning survival associated with the use of high-dose AT in severe sepsis patients but showed a trend towards a reduction in mortality at 28 and 90 days in the subgroup of patients without concomitant heparin therapy [ 34 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.